The Pan-Cancer Analysis Uncovers the Prognostic and Immunotherapeutic Significance of CD19 as an Immune Marker in Tumor
DOI: https://doi.org/10.2147/ijgm.s459914
IF: 2.145
2024-06-04
International Journal of General Medicine
Abstract:Lanyi Wei, Jingjing Meng, Danfeng Xiang, Quanjun Yang, Yangyun Zhou, Lingyan Xu, Junjun Chen, &ast Yonglong Han &ast Department of Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China &astThese authors contributed equally to this work Correspondence: Junjun Chen; Yonglong Han, Department of Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China, Email ; Background: The specific cytotoxic effects of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy have led to impressive outcomes in individuals previously treated for B-cell malignancies. However, the specific biological role of CD19(+) target cells, which exert antitumor immunity against some solid tumors, remains to be elucidated. Methods: We collected information regarding the level of CD19 mRNA and protein expression from various databases including The Cancer Genome Atlas (TCGA), Tumor Immune Estimation Resource (TIMER), Genotype-Tissue Expression (GTEx), and Human Protein Atlas (HPA) for both tumor and normal samples. To evaluate the patient's prognosis according to CD19 expression, a Kaplan-Meier (KM) analysis and univariate Cox regression were performed. Furthermore, using the Estimation of Stromal and Immune Cells in Malignant Tumor Tissues Using the Expression Data (ESTIMATE) algorithm, we estimated the ratio of immune cells infiltrating malignant tumor tissues. Afterward, the GSCALite repository was employed to evaluate the vulnerability of tumors expressing CD19 to drugs used in chemotherapy. To validate the results in clinical samples of certain cancer types, immunohistochemistry was then performed. Results: Most tumor types exhibited CD19 expression differently, apart from colon adenocarcinoma (COAD). The early diagnostic value of CD19 has been demonstrated in 9 different tumor types, and the overexpression of CD19 has the potential to extend the survival duration of patients. Multiple tumors showed a positive correlation between CD19 expression and tumor mutation burden (TMB), microsatellite instability (MSI), and ESTIMATE score. Furthermore, a direct association was discovered between the expression of CD19 and the infiltration of immune cells, particularly in cases of breast invasive carcinoma (BRCA). Moreover, CD19 is highly sensitive to a variety of chemotherapy drugs. Conclusion: The study reveals the potential of CD19 as both a predictive biomarker and a target for different cancer immunotherapies. Keywords: CD19, pan-cancer, prognosis, immune infiltration, biomarker Immunotherapy has gained popularity as a preferred approach for treating cancer due to the achievements of monoclonal antibody-based immune checkpoint blockade and engineered T cells. 1 Stimulatory and inhibitory pathways found in immune checkpoints assist in boosting the immune system's reaction to tumors while maintaining self-tolerance. The main observation is the blocking of pathways such as cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death ligand-1 (PD-L1). 2 Studies have shown that PD-L1 in breast cancer cells can facilitate the differentiation of CD19(+) B cells and aid in the evasion of immune cells. 3 Chimeric antigen receptor (CAR) -T cells have shown potential as an alternative immunotherapy method because they can identify antigens associated with tumors on the outer layer of tumor cells and gene products on the outer layer of healthy cells. 4,5 The primary application of these cells has been for the treatment of blood cancers, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. Although the effectiveness of this treatment has been less noticeable in solid tumors, there have been encouraging results observed in neuroblastoma, non-small cell lung cancer, melanoma, breast cancer, and sarcoma (SARC). 6,7 There is a documented association between the level of CD19 expression in tumors and the effectiveness of engineered T cells in causing cell death. 8 Therapies targeting CD19 include CAR-T cell therapy, monoclonal antibodies, bispecific antibodies, and targeted antibody-drug couplings. 9 Among them, the impressive clinical reactions of resistant B-cell cancers to the transfer of anti-CD19 CAR-engineered T cells have emphasized the crucial function of CD19 protein in the treatment of different tumors. 10 Consequently, it is necessary to investigate the different levels of CD19 expression in all types of cancers and their impact on the immune system. The -Abstract Truncated-
medicine, general & internal